https://edgen.beta.edgen.tech/ja/news/post/black-diamond-rises-on-152-month-cancer-trial-result2026-05-21T21:33:27.094Zdaily1Edgen Stockja2026-05-21T21:33:27.094+00:00ブラック・ダイヤモンド、15.2ヶ月のがん治験結果を受けて株価上昇https://static.edgen.tech/news/images/black-diamond-rises-on-152-month-cancer-trial-result-20260521.pngブラック・ダイヤモンド、15.2ヶ月のがん治験結果を受けて株価上昇 https://edgen.beta.edgen.tech/ja/news/post/why-a-9010-portfolio-may-be-better-than-6040-for-some-investors2026-05-21T21:32:58.991Zdaily1Edgen Stockja2026-05-21T21:32:58.991+00:00なぜ一部の投資家にとって 90/10 ポートフォリオが 60/40 よりも優れている可能性があるのかhttps://static.edgen.tech/news/images/why-a-9010-portfolio-may-be-better-than-6040-for-some-investors-20260521.pngなぜ一部の投資家にとって 90/10 ポートフォリオが 60/40 よりも優れている可能性があるのか https://edgen.beta.edgen.tech/ja/news/post/merck-lung-cancer-combo-with-kelun-hits-70-response-rate2026-05-21T21:32:56.818Zdaily1Edgen Stockja2026-05-21T21:32:56.818+00:00メルクとケルンの肺がん併用療法、奏効率70％を達成https://static.edgen.tech/news/images/merck-lung-cancer-combo-with-kelun-hits-70-response-rate-20260521.pngメルクとケルンの肺がん併用療法、奏効率70％を達成 https://edgen.beta.edgen.tech/ja/news/post/imax-surges-15-on-reports-of-a-potential-sale2026-05-21T21:30:25.375Zdaily1Edgen Stockja2026-05-21T21:30:25.375+00:00IMAX、売却検討の報道で株価が15%急騰https://static.edgen.tech/news/images/imax-surges-15-on-reports-of-a-potential-sale-20260521.pngIMAX、売却検討の報道で株価が15%急騰 https://edgen.beta.edgen.tech/ja/news/post/bicara-cancer-drug-doubles-survival-rate-to-31-in-head-and-neck-trial2026-05-21T21:29:39.793Zdaily1Edgen Stockja2026-05-21T21:29:39.793+00:00Bicaraの癌治療薬、頭頸部がん治験で生存率を31%に倍増https://static.edgen.tech/news/images/bicara-cancer-drug-doubles-survival-rate-to-31-in-head-and-neck-trial-20260521.pngBicaraの癌治療薬、頭頸部がん治験で生存率を31%に倍増 https://edgen.beta.edgen.tech/ja/news/post/syndax-to-present-new-revuforj-data-from-4-leukemia-trials-at-asco2026-05-21T21:28:59.514Zdaily1Edgen Stockja2026-05-21T21:28:59.514+00:00シンダックス、ASCOで白血病薬レブフォルジの4つの臨床試験データを発表へhttps://static.edgen.tech/news/images/syndax-to-present-new-revuforj-data-from-4-leukemia-trials-at-asco-20260521.pngシンダックス、ASCOで白血病薬レブフォルジの4つの臨床試験データを発表へ https://edgen.beta.edgen.tech/ja/news/post/remix-drug-shows-43-response-rate-in-rare-cancer-trial2026-05-21T21:26:23.159Zdaily1Edgen Stockja2026-05-21T21:26:23.159+00:00Remixの薬、希少がん治験で43%の奏効率を記録https://static.edgen.tech/news/images/remix-drug-shows-43-response-rate-in-rare-cancer-trial-20260521.pngRemixの薬、希少がん治験で43%の奏効率を記録 https://edgen.beta.edgen.tech/ja/news/post/akaris-cancer-drug-shows-high-synergy-with-kras-inhibitors2026-05-21T21:26:17.852Zdaily1Edgen Stockja2026-05-21T21:26:17.852+00:00Akariの癌治療薬、KRAS阻害剤との高い相乗効果を示すhttps://static.edgen.tech/news/images/akaris-cancer-drug-shows-high-synergy-with-kras-inhibitors-20260521.pngAkariの癌治療薬、KRAS阻害剤との高い相乗効果を示す https://edgen.beta.edgen.tech/ja/news/post/dow-surges-351-points-to-new-record-as-investors-rotate-to-tech2026-05-21T21:25:30.072Zdaily1Edgen Stockja2026-05-21T21:25:30.072+00:00投資家がハイテク株へシフト、ダウ平均は351ドル高で最高値更新https://static.edgen.tech/news/images/dow-surges-351-points-to-new-record-as-investors-rotate-to-tech-20260521.png投資家がハイテク株へシフト、ダウ平均は351ドル高で最高値更新 https://edgen.beta.edgen.tech/ja/news/post/seer-rejects-radoff-jecs-240-per-share-takeover-bid2026-05-21T20:56:36.929Zdaily1Edgen Stockja2026-05-21T20:56:36.929+00:00Seer、Radoff-JECによる1株2.40ドルの買収提案を拒否https://static.edgen.tech/news/images/seer-rejects-radoff-jecs-240-per-share-takeover-bid-20260521.pngSeer、Radoff-JECによる1株2.40ドルの買収提案を拒否 https://edgen.beta.edgen.tech/ja/news/post/lucid-group-faces-fraud-inquiry-after-revenue-miss-sinks-stock-72026-05-21T20:55:36.196Zdaily1Edgen Stockja2026-05-21T20:55:36.196+00:00ルーシッド・グループ、売上高の未達で株価が7%下落、詐欺罪の疑いで調査を受けるhttps://static.edgen.tech/news/images/lucid-group-faces-fraud-inquiry-after-revenue-miss-sinks-stock-7-20260521.pngルーシッド・グループ、売上高の未達で株価が7%下落、詐欺罪の疑いで調査を受ける https://edgen.beta.edgen.tech/ja/news/post/baycom-stock-drops-11-as-law-firm-probes-executive-exodus2026-05-21T20:55:26.700Zdaily1Edgen Stockja2026-05-21T20:55:26.700+00:00幹部の一斉退任に伴う法律事務所の調査でBayCom株が11％下落https://static.edgen.tech/news/images/baycom-stock-drops-11-as-law-firm-probes-executive-exodus-20260521.png幹部の一斉退任に伴う法律事務所の調査でBayCom株が11％下落 https://edgen.beta.edgen.tech/ja/news/post/carmax-faces-investor-investigation-after-stock-plunges-152026-05-21T20:55:23.871Zdaily1Edgen Stockja2026-05-21T20:55:23.871+00:00カーマックス、株価15%急落で投資家による調査に直面https://static.edgen.tech/news/images/carmax-faces-investor-investigation-after-stock-plunges-15-20260521.pngカーマックス、株価15%急落で投資家による調査に直面 https://edgen.beta.edgen.tech/ja/news/post/abbvies-boey-gets-positive-eu-opinion-for-30-markets2026-05-21T20:31:26.478Zdaily1Edgen Stockja2026-05-21T20:31:26.478+00:00アッヴィのBoey、欧州30市場で肯定的見解を獲得https://static.edgen.tech/news/images/abbvies-boey-gets-positive-eu-opinion-for-30-markets-20260521.pngアッヴィのBoey、欧州30市場で肯定的見解を獲得 https://edgen.beta.edgen.tech/ja/news/post/ralph-lauren-stock-soars-10-on-strong-q4-earnings2026-05-21T20:30:58.085Zdaily1Edgen Stockja2026-05-21T20:30:58.085+00:00ラルフローレン、好調な第4四半期決算を受けて株価が10%急騰https://static.edgen.tech/news/images/ralph-lauren-stock-soars-10-on-strong-q4-earnings-20260521.pngラルフローレン、好調な第4四半期決算を受けて株価が10%急騰 https://edgen.beta.edgen.tech/ja/news/post/inovio-partner-reports-positive-phase-3-data-for-hpv-drug2026-05-21T20:27:14.890Zdaily1Edgen Stockja2026-05-21T20:27:14.890+00:00Inovioのパートナー、HPV治療薬の第3相試験で良好な結果を報告https://static.edgen.tech/news/images/inovio-partner-reports-positive-phase-3-data-for-hpv-drug-20260521.pngInovioのパートナー、HPV治療薬の第3相試験で良好な結果を報告 https://edgen.beta.edgen.tech/ja/news/post/revolution-medicines-to-reveal-data-after-daraxonrasib-nearly-doubles-survival-in-phase-3-trial2026-05-21T20:27:11.730Zdaily1Edgen Stockja2026-05-21T20:27:11.730+00:00Revolution Medicines、daraxonrasibが第3相試験で生存期間をほぼ倍増させたことを受けデータ公開へhttps://static.edgen.tech/news/images/revolution-medicines-to-reveal-data-after-daraxonrasib-nearly-doubles-survival-in-phase-3-trial-20260521.pngRevolution Medicines、daraxonrasibが第3相試験で生存期間をほぼ倍増させたことを受けデータ公開へ https://edgen.beta.edgen.tech/ja/news/post/oura-files-for-ipo-at-11b-valuation-as-smart-ring-sales-double2026-05-21T20:26:01.593Zdaily1Edgen Stockja2026-05-21T20:26:01.593+00:00OuraがIPOを申請、評価額110億ドル　スマートリングの売上倍増でhttps://static.edgen.tech/news/images/oura-files-for-ipo-at-11b-valuation-as-smart-ring-sales-double-20260521.pngOuraがIPOを申請、評価額110億ドル　スマートリングの売上倍増で https://edgen.beta.edgen.tech/ja/news/post/trump-demands-irans-uranium-as-talks-near-90-day-mark2026-05-21T20:25:48.712Zdaily1Edgen Stockja2026-05-21T20:25:48.712+00:00交渉開始から90日を前にトランプ氏がイランにウラン引き渡しを要求https://static.edgen.tech/news/images/trump-demands-irans-uranium-as-talks-near-90-day-mark-20260521.png交渉開始から90日を前にトランプ氏がイランにウラン引き渡しを要求 https://edgen.beta.edgen.tech/ja/news/post/fiverr-stock-drops-over-8-after-investor-rights-firm-probe2026-05-21T19:56:00.616Zdaily1Edgen Stockja2026-05-21T19:56:00.616+00:00Fiverr株、投資家権利保護法人による調査を受けて8%超下落https://static.edgen.tech/news/images/fiverr-stock-drops-over-8-after-investor-rights-firm-probe-20260521.pngFiverr株、投資家権利保護法人による調査を受けて8%超下落